6-K - InflaRx N.V. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

InflaRx N.V. reported full year 2025 financial results with a net loss of €45.6 million or €0.68 per share and cash, cash equivalents, and marketable securities of €46.2 million as of December 31, 2025, expected to fund operations to mid-2027. The company highlighted promising Phase 2a data for izicopan in HS and CSU, progress toward Phase 2b readiness in HS, and plans for a PK bridging study in China.

Key Takeaways

1Positive Phase 2a topline data for izicopan in HS and CSU announced November 2025, with rapid improvements in HiSCR, IHS4, NRS30, DLQI from Week 1.

2Substantial progress toward Phase 2b readiness for izicopan in HS; active FDA discussions expected to close in upcoming months.

3Cash, cash equivalents, and marketable securities totaled €46.2 million on December 31, 2025, expected to fund operations to mid-2027.

4Net loss of €45.6 million or €0.68 per ordinary share for year ended December 31, 2025, compared to €46.1 million or €0.78 per share in 2024.

5Intends to conduct pharmacokinetic bridging study with izicopan in China this year to support proof-of-concept in additional I&I indications.

6Post-hoc analyses of vilobelimab Phase 3 in PG show positive trends in remission, ulcer volume reduction, DLQI.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Results of Operations

Full Year 2025

Metric	Value	Basis	Prior Period
Revenues	$0.03	GAAP	$0.17
Net Loss	$-45.60	GAAP	$-46.10
Loss per share (basic/diluted)	$-0.68	GAAP	$-0.78

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE, DATED MARCH 19, 2026